Nope, but cheap IP is for other Pharma companies. Be mindful of other companies making progression in the space and the possibility that someone picks this up in a fire sale for an easy route to a well patented approach to reliable potency assays in MSc delivery - a hurdle for some companies with regulators in the space.
$7 million mkt cap would be less than the stationary expenses of some of the larger Pharmas'.
Ann: Notice of Termination of Kyocera Licence, page-15
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
